EGFR and colorectal cancer: Objective responses were not noted in the 11 patients treated with low-dose brivanib group, despite concomitant cetuximab therapy, possibly because of the low number of patients in this subgroup and the inclusion of patients with gastrointestinal malignancies other than colorectal cancer (where cetuximab does not have a proven efficacy as monotherapy), patients with unknown K-Ras status and patients who had received prior anti-EGFR therapies.